US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading
Executive Summary
The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.
You may also be interested in...
Metuchen Must Correct ED Drug Ads For Adult Sites After US FDA Warning Letter
Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.
Do Consumers Understand TV Ads For Oncology Drugs?
US FDA plans to conduct a study to evaluate consumer comprehension of oncology indications in direct-to-consumer television advertising.
US FDA Should Regulate Ads Soliciting Mass Tort Suits, Group Says
Citing deaths and injuries caused when people stopped talking Xarelto in response to advertisements, US Chamber Institute for Legal Reform recommends Congress give FDA authority to halt misleading lawsuit ads.